Wells Fargo
FATE icon

Wells Fargo’s Fate Therapeutics FATE Stock Holding History

Wells Fargo’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-17,000
Closed -$74K – 6611
2020
Q3 		$74K Buy
+17,000
New +$594K ﹤0.01% 5367

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo's FATE Position: Q1 2026 in Review

Wells Fargo reduced its Fate Therapeutics (FATE) stake by 41% in Q1 2026, selling an estimated $86.8K and leaving 100,975 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #4996.

Wells Fargo first reported a position in FATE in Q1 2014 and has held it in 47 quarters since. The position peaked at $28.4M in Q2 2021. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Wells Fargo held 100,975 shares of Fate Therapeutics worth $121K as of Q1 2026.
  • Wells Fargo sold 71,308 Fate Therapeutics shares in Q1 2026, an estimated $86.8K.
  • Fate Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4996 holding.
  • Wells Fargo first reported a position in Fate Therapeutics in Q1 2014 and has held it in 47 quarters since.
  • Wells Fargo's Fate Therapeutics position peaked at $28.4M in Q2 2021.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.